N/A
Completed N=57
Screening for HPV and Cervical Cancer in Young Women With Perinatally Acquired HIV
Source: ClinicalTrials.gov NCT04587050 ↗Enrolled (actual)
57
Serious AEs
0.0%
Results posted
Dec 2024
Primary outcomePrimary: Prevalence of Abnormal Cervical Cytology — 12 Participants
Summary
This is a cross-sectional, observational study of high-risk HPV status, cervical cytology and HPV vaccine uptake and response in young women with perinatally acquired HIV.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Prevalence of Abnormal Cervical Cytology |
12 | — |
| SECONDARY Prevalence of High Risk HPV by Subtype |
2; 0; 12; 32 | — |
| SECONDARY Prevalence of CIN2+ |
1 | — |
| SECONDARY HPV Serology (16/18) |
44; 1; 34; 0 | — |
Eligibility Criteria
Inclusion Criteria - Cohort 1:
- Perinatally acquired HIV aged 18+
- Sexually active
- Able to give informed consent
Inclusion Criteria - Cohort 2:
- Perinatally acquired HIV aged 18+
- Able to give informed consent
Exclusion Criteria - Cohort 1:
- Pregnancy
- Not sexually active
- Previous total abdominal hysterectomy
- Unable to give informed consent
Exclusion Criteria - Cohort 2:
- Unable to give informed consent
Data sourced from ClinicalTrials.gov (NCT04587050). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.